Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients with Steroid-Refractory Pneumonitis

Inclusion Criteria

• Patient must be >= 18 years of age
• Patients must be English-speaking and have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible
• Patient must be willing and able to undergo arterial blood gas assessment as per the treating investigator. Patient must not have contraindication for arterial blood gas assessment
• Women must not be pregnant or breast-feeding due to the potential risk to the fetus with infliximab or IVIG. All females of childbearing potential must have a blood test or urine test within 14 days prior to randomization to rule out pregnancy. A female of childbearing potential is defined as any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
• Women of childbearing potential and sexually active males must not conceive or father children by using accepted and effective method(s) of contraception or to abstain from sexual intercourse for a minimum of 56 days (the duration of their participation in the study)
• Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-3
• Patient with any solid tumor or hematologic malignancy is eligible * NOTE: Patient may have received any number of lines of prior systemic therapy
• Patient must have received treatment with an anti-PD-1/PD-L1 agent either alone or in combination with another anti-cancer agent, as their most recent therapy prior to development of pneumonitis * NOTE: Patient may have received anti-PD-1/PD-L1 therapy as standard-of-care or part of a clinical trial
• Patient must have steroid-refractory pneumonitis defined as: * Grade 2 pneumonitis that has not clinically improved by a Common Terminology Criteria for Adverse Events (CTCAE) grade in greater than 72 hours or maximum of 21 days or * Grade 3 or higher pneumonitis that has not clinically improved by a CTCAE grade in greater than 48 hours or maximum of 21 days with high dose corticosteroids (methylprednisolone or prednisone 1-4 mg/kg/equivalent) as their most recent treatment for pneumonitis, as determined by the treating investigator * CTCAE grade 1 radiographic findings
• Patient must have had pathogen-negative infectious diagnostic evaluation within 21 days prior to randomization, and at a minimum these should include: blood culture, urine culture, sputum culture, and viral panel: rapid flu and RSV (respiratory syncytial virus). Empiric antibiotics for culture negative infections are not an exclusion for study entry
• Patient must have a negative tuberculosis assessment (TB spot test, quantiferon gold or tuberculin skin test) within 21 days prior to randomization and either negative or low clinical suspicion
• Patient must have chest CT scan with or without contrast performed =< 14 days before randomization. Patient must not have a contraindication for CT

Exclusion Criteria

• Patient must not be receiving anti-PD-1/-PD-L1 agent in combination with any of the following anti-cancer agents: docetaxel, cyclophosphamide, gefitinib, erlotinib, osimertinib, crizotinib, bleomycin, afatinib
• Patient must not have clinical evidence of cardiac dysfunction (as determined by the treating investigator) as an alternative diagnosis to steroid-refractory pneumonitis
• Patient must not be receiving concurrent radiation therapy to the chest
• Patient must not be deemed to have radiation pneumonitis. Patients with a history of stable radiation pneumonitis not requiring corticosteroid therapy within the last 3 months prior to randomization will be allowed on study
• Patient must not have pre-existing interstitial lung disease or pneumonitis requiring corticosteroid therapy from any other cause, as determined by the treating investigator
• Patient must not have an absolute contraindication to IVIG or infliximab, including: clinical history of severe hypersensitivity reaction, selective IgA deficiency, active hepatitis B, active tuberculosis, active human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) where a study subject has a CD4 count of =< 200 at screening, or drug interaction